Wrapmanager Inc. Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Wrapmanager Inc. increased its stake in Johnson & Johnson (NYSE:JNJ) by 25.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,416 shares of the company’s stock after buying an additional 2,887 shares during the period. Wrapmanager Inc.’s holdings in Johnson & Johnson were worth $2,107,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Stolper Co increased its stake in Johnson & Johnson by 3.9% during the 2nd quarter. Stolper Co now owns 33,730 shares of the company’s stock valued at $4,930,000 after purchasing an additional 1,279 shares in the last quarter. Leelyn Smith LLC increased its position in shares of Johnson & Johnson by 2.6% during the second quarter. Leelyn Smith LLC now owns 16,950 shares of the company’s stock valued at $2,477,000 after acquiring an additional 435 shares in the last quarter. Stoneridge Investment Partners LLC raised its holdings in Johnson & Johnson by 25.0% in the 2nd quarter. Stoneridge Investment Partners LLC now owns 20,221 shares of the company’s stock worth $2,956,000 after acquiring an additional 4,038 shares during the last quarter. Dai ichi Life Insurance Company Ltd lifted its position in Johnson & Johnson by 2.3% in the 2nd quarter. Dai ichi Life Insurance Company Ltd now owns 221,653 shares of the company’s stock valued at $32,397,000 after acquiring an additional 5,023 shares in the last quarter. Finally, Schiavi & Co LLC boosted its stake in Johnson & Johnson by 11.4% during the 2nd quarter. Schiavi & Co LLC now owns 3,136 shares of the company’s stock valued at $458,000 after purchasing an additional 320 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.5 %

NYSE JNJ opened at $165.52 on Friday. The stock’s 50-day moving average price is $159.55 and its 200-day moving average price is $153.99. The company has a market capitalization of $398.45 billion, a P/E ratio of 10.32, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.80 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were issued a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on JNJ shares. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. TD Cowen dropped their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. The Goldman Sachs Group cut their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.